Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Drug target identification and quantitative proteomics.

He T, Jin Kim Y, Heidbrink JL, Moore PA, Ruben SM.

Expert Opin Drug Discov. 2006 Oct;1(5):477-89. doi: 10.1517/17460441.1.5.477.

PMID:
23495947
2.

Proteomics: technologies for protein analysis.

Gomase VS, Kale KV, Tagore S, Hatture SR.

Curr Drug Metab. 2008 Mar;9(3):213-20. Review.

PMID:
18336224
3.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
4.

Limitations of current proteomics technologies.

Garbis S, Lubec G, Fountoulakis M.

J Chromatogr A. 2005 Jun 3;1077(1):1-18. Review.

PMID:
15988981
5.

Identification of novel targets for cancer therapy using expression proteomics.

Hanash SM, Madoz-Gurpide J, Misek DE.

Leukemia. 2002 Apr;16(4):478-85. Review.

6.

The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development.

Mikami T, Aoki M, Kimura T.

Curr Mol Pharmacol. 2012 Jun;5(2):301-16. Review.

PMID:
22122469
7.

Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.

Matta A, Ralhan R, DeSouza LV, Siu KW.

Mass Spectrom Rev. 2010 Nov-Dec;29(6):945-61. doi: 10.1002/mas.20296. Review.

PMID:
20945361
8.

Chemical proteomics and its impact on the drug discovery process.

Miao Q, Zhang CC, Kast J.

Expert Rev Proteomics. 2012 Jun;9(3):281-91. doi: 10.1586/epr.12.22. Review.

PMID:
22809207
9.

Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases.

Cho CH, Nuttall ME.

Expert Opin Ther Targets. 2002 Dec;6(6):679-89. Review.

PMID:
12472380
10.

Proteomics in developmental toxicology.

Barrier M, Mirkes PE.

Reprod Toxicol. 2005 Jan-Feb;19(3):291-304. Review.

PMID:
15686865
11.

Applications of current proteomics techniques in modern drug design.

Zhang CC, Kast J.

Curr Comput Aided Drug Des. 2010 Sep;6(3):147-64. Review.

PMID:
20438442
12.

Quantitative proteomics for cancer biomarker discovery.

Liang S, Xu Z, Xu X, Zhao X, Huang C, Wei Y.

Comb Chem High Throughput Screen. 2012 Mar;15(3):221-31. Review.

PMID:
22221055
13.

Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.

Fredolini C, Liotta LA, Petricoin EF.

Crit Rev Clin Lab Sci. 2010 May-Jun;47(3):125-38. doi: 10.3109/10408363.2010.503558. Epub 2010 Sep 21. Review.

PMID:
20858067
14.

Driving biochemical discovery with quantitative proteomics.

Washburn MP.

Trends Biochem Sci. 2011 Mar;36(3):170-7. doi: 10.1016/j.tibs.2010.09.001. Epub 2010 Sep 27. Review.

PMID:
20880711
15.

Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.

Elschenbroich S, Kislinger T.

Mol Biosyst. 2011 Feb;7(2):292-303. doi: 10.1039/c0mb00159g. Epub 2010 Oct 25. Review.

PMID:
20976349
16.

Application of LC/MS to proteomics studies: current status and future prospects.

Chen G, Pramanik BN.

Drug Discov Today. 2009 May;14(9-10):465-71. doi: 10.1016/j.drudis.2009.02.007. Epub 2009 Feb 26. Review.

PMID:
19429505
17.

Proteomic methods for drug target discovery.

Sleno L, Emili A.

Curr Opin Chem Biol. 2008 Feb;12(1):46-54. doi: 10.1016/j.cbpa.2008.01.022. Epub 2008 Mar 7. Review.

PMID:
18282485
18.

Application of proteomic technologies in the drug development process.

Walgren JL, Thompson DC.

Toxicol Lett. 2004 Apr 1;149(1-3):377-85. Review.

PMID:
15093284
19.

Proteomics: addressing the challenges of multiple myeloma.

Ge F, Tao S, Bi L, Zhang Z, Zhang X.

Acta Biochim Biophys Sin (Shanghai). 2011 Feb;43(2):89-95. doi: 10.1093/abbs/gmq120. Epub 2011 Jan 5. Review.

PMID:
21212069
20.

Supplemental Content

Support Center